Kyowa Kirin’s Nourianz (istradefylline) Receives FDA’s Approval as an Adjunctive Therapy in Patients with Parkinson’s Disease

 Kyowa Kirin’s Nourianz (istradefylline) Receives FDA’s Approval as an Adjunctive Therapy in Patients with Parkinson’s Disease

AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)

Shots:

  • The US FDA has granted approval to Nourianz for use as an add-on treatment to levodopa/carbidopa and is based on clinical studies assessing Nourianz vs PBO in PD patients experiencing “OFF” episodes, administering a stable dose of levodopa/carbidopa with/out other PD therapies
  • The four clinical study results demonstrated that adjunct to levodopa/carbidopa, istradefylline improves OFF time and is well tolerated among the patients
  • Nourianz (PO) is a selective adenosine A2A receptor antagonist and is marketed under the trade name as Nouriast in Japan indicated for the improvement of the wearing-off phenomenon in patients with PD, since May 30, 2013

Click here to­ read full press release/ article | Ref: Kyowa Kirin | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post